- Home
- BTBD vs RLMD Comparison
BTBD vs RLMD Comparison
Compare BTBD & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBD
- RLMD
- Stock Information
- Founded
- BTBD 1987
- RLMD 2004
- Country
- BTBD United States
- RLMD United States
- Employees
- BTBD N/A
- RLMD N/A
- Industry
- BTBD Restaurants
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- BTBD Consumer Discretionary
- RLMD Health Care
- Exchange
- BTBD Nasdaq
- RLMD Nasdaq
- Market Cap
- BTBD 9.8M
- RLMD 11.5M
- IPO Year
- BTBD 2021
- RLMD N/A
- Fundamental
- Price
- BTBD $1.58
- RLMD $0.39
- Analyst Decision
- BTBD
- RLMD Hold
- Analyst Count
- BTBD 0
- RLMD 4
- Target Price
- BTBD N/A
- RLMD $4.25
- AVG Volume (30 Days)
- BTBD 9.4K
- RLMD 881.7K
- Earning Date
- BTBD 11-13-2024
- RLMD 03-18-2025
- Dividend Yield
- BTBD N/A
- RLMD N/A
- EPS Growth
- BTBD N/A
- RLMD N/A
- EPS
- BTBD N/A
- RLMD N/A
- Revenue
- BTBD $14,647,844.00
- RLMD N/A
- Revenue This Year
- BTBD N/A
- RLMD N/A
- Revenue Next Year
- BTBD N/A
- RLMD N/A
- P/E Ratio
- BTBD N/A
- RLMD N/A
- Revenue Growth
- BTBD 4.20
- RLMD N/A
- 52 Week Low
- BTBD $1.25
- RLMD $0.34
- 52 Week High
- BTBD $2.32
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- BTBD 48.44
- RLMD 27.66
- Support Level
- BTBD $1.46
- RLMD $0.36
- Resistance Level
- BTBD $1.85
- RLMD $0.49
- Average True Range (ATR)
- BTBD 0.11
- RLMD 0.05
- MACD
- BTBD -0.00
- RLMD 0.07
- Stochastic Oscillator
- BTBD 35.42
- RLMD 17.28
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.